New hope for ovarian cancer patients in drug interaction trial
NCT ID NCT07341100
Summary
This study is testing a new drug called SKB264 for women with recurrent ovarian cancer. It aims to see if the drug helps control the cancer and checks how a common antibiotic (clarithromycin) affects the drug's levels in the body. About 20 participants will receive the drug, and researchers will monitor their response and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN EPITHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.